Recent studies on retatrutide, a dual stimulant for glucagon-like peptide-1 and gastric inhibitory polypeptide, indicate promising findings in addressing obesity and type 2 diabetes. Initial data from clinical experiments point to substantial decreases in body bulk and bettered glucose regulation. Additional examination is centered on long-term saf